"I'm excited about Quanta Services (PWR), a contracting company that specializes in building utility transmission and distribution infrastructure," says Ian Wyatt.

In his Top Stock Insights, he explains, "The current focus in the U.S. of projects that improve energy conservation, utilize renewable resources, and improve air quality make Quanta an excellent long-term growth opportunity.

"Its customers are in the electric power, gas, telecommunications, and cable television industries. These are stimulus spending customers; i.e., big government organizations and utilities companies.

"I am recommending Celgene (NASDAQ: CELG) as part of an 'offense-defense' thesis," says Ian Wyatt. In Top Stock Insights, he reviews the leading biotechnology company.

Wyatt explains, "Celgene engages in the discovery of therapies designed to treat cancer and immune inflammatory related diseases. They have a number of products at the commercial stage including REVLIMID, THALOMID and VIDAZA.

"Celgene is also researching stem cells derived from the human placenta as well as from the umbilical cord, thus tapping into a promising new technology while avoiding the political and ethical questions dogging others involved in stem cell research.

"International Business Machines (NYSE: IBM) has transformed itself into a dynamic consulting and computer services company that's leading the charge to help companies streamline efficiency and cut costs," says Ian Wyatt.

In his Top Stock Insights he explains, "And most investors are unaware of the change. In our opinion, that's why IBM trades with such an attractive valuation."

"The transformation of IBM means there should be some solid profits for investors who understand the changing face of business. It started in 2002. IBM bought out PricewaterhouseCoopers Consulting for $3.5 billion.

"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.

In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."

"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.

"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.

This post is part of a 12-article feature on the best bets for investing in China. To see all the other recommendations in this special report, click here.

"Mindray Medical International (NYSE: MR), based in Shenzhen, China and run by entrepreneurs, is a great defensive growth play," says Ian Wyatt in Top Stock Insights.Here's his review.

"This maker of medical devices boasts a strong brand and sales network with heavy investments in R&D and a smorgasbord of products.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"Situated well within a niche that appears to be an oasis in the desert is gaming machine maker WMS Industries (NYSE: WMS)," says growth stock specialist Ian Wyatt.

The editor of Top Stock Insights explains, "Gaming technology has not struggled as much as casino operators as there is still a need for new equipment to drive traffic to casinos."

The advisor continues, "WMS is engaged in the design, manufacture, and distribution of gaming machines and video lottery terminals (VLTs) for customers in gaming jurisdictions worldwide. Its offering consists of video gaming machines, mechanical reel gaming machines, and video poker gaming machines.

"While gaming certainly has taken a hit in the wake of the economic downturn, slot machine makers operate in a unique space that may be one of the few that has the ability to weather economic volatility, as states look to slots as a way to boost tax receipts.

"Rivals may be creating a buzz in the market for navigational technologies, but Garmin Ltd. (Nasdaq: GRMN) will fight off its rivals as it always has, with product breadth and innovation," says Ian Wyatt in Top Stock Insights.

"Garmin, which first started selling products in 1991, has been on a run. Since 2001, the company has compound annual revenue growth of 30%; net income has grown 29% compounded annually.

"Through sound financial execution, Garmin has become a worldwide leader in providing navigation, communication and information devices, many of which carry global positioning system (GPS) technology.

"The automotive and mobile division, which represents the company's portable navigation devices (PNDs), dominates the company's business. PNDs are the fastest growing, most competitive and most consequential market for Garmin and accounted for 71.2% of revenue in third quarter of fiscal 2007.

"In the North American PND market Garmin's share is more than 50%, and its PND share in Europe is 20%. Itss market share is greater than 60% in aviation and higher than 30% in marine electronics. The company's main geographic market is North America, followed by Europe, and then - to a much smaller extent - Asia.